TY - JOUR
T1 - Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050
T2 - a systematic analysis for the Global Burden of Disease Study 2021
AU - GBD 2021 Osteoarthritis Collaborators
AU - Steinmetz, Jaimie D.
AU - Culbreth, Garland T.
AU - Haile, Lydia M.
AU - Rafferty, Quinn
AU - Lo, Justin
AU - Fukutaki, Kai Glenn
AU - Cruz, Jessica A.
AU - Smith, Amanda E.
AU - Vollset, Stein Emil
AU - Brooks, Peter M.
AU - Cross, Marita
AU - Woolf, Anthony D.
AU - Hagins, Hailey
AU - Abbasi-Kangevari, Mohsen
AU - Abedi, Aidin
AU - Ackerman, Ilana N.
AU - Amu, Hubert
AU - Antony, Benny
AU - Arabloo, Jalal
AU - Aravkin, Aleksandr Y.
AU - Argaw, Ayele Mamo
AU - Artamonov, Anton A.
AU - Ashraf, Tahira
AU - Barrow, Amadou
AU - Bearne, Lindsay M.
AU - Bensenor, Isabela M.
AU - Berhie, Alemshet Yirga
AU - Bhardwaj, Nikha
AU - Bhardwaj, Pankaj
AU - Bhojaraja, Vijayalakshmi S.
AU - Bijani, Ali
AU - Briant, Paul Svitil
AU - Briggs, Andrew M.
AU - Butt, Nadeem Shafique
AU - Charan, Jaykaran
AU - Chattu, Vijay Kumar
AU - Cicuttini, Flavia M.
AU - Coberly, Kaleb
AU - Dadras, Omid
AU - Dai, Xiaochen
AU - Dandona, Lalit
AU - Dandona, Rakhi
AU - de Luca, Katie
AU - Denova-Gutiérrez, Edgar
AU - Dharmaratne, Samath Dhamminda
AU - Dhimal, Meghnath
AU - Dianatinasab, Mostafa
AU - Dreinhoefer, Karsten E.
AU - Elhadi, Muhammed
AU - Farooque, Umar
AU - Farpour, Hamid Reza
AU - Filip, Irina
AU - Fischer, Florian
AU - Freitas, Marisa
AU - Ganesan, Balasankar
AU - Gemeda, Belete Negese Belete
AU - Getachew, Tamiru
AU - Ghamari, Seyyed Hadi
AU - Ghashghaee, Ahmad
AU - Gill, Tiffany K.
AU - Golechha, Mahaveer
AU - Golinelli, Davide
AU - Gupta, Bhawna
AU - Gupta, Veer Bala
AU - Gupta, Vivek Kumar
AU - Haddadi, Rasool
AU - Hafezi-Nejad, Nima
AU - Halwani, Rabih
AU - Hamidi, Samer
AU - Hanif, Asif
AU - Harlianto, Netanja I.
AU - Haro, Josep Maria
AU - Hartvigsen, Jan
AU - Hay, Simon I.
AU - Hebert, Jeffrey J.
AU - Heidari, Golnaz
AU - Hosseini, Mohammad Salar
AU - Hosseinzadeh, Mehdi
AU - Hsiao, Alexander Kevin
AU - Ilic, Irena M.
AU - Ilic, Milena D.
AU - Jacob, Louis
AU - Jayawardena, Ranil
AU - Jha, Ravi Prakash
AU - Jonas, Jost B.
AU - Joseph, Nitin
AU - Kandel, Himal
AU - Karaye, Ibraheem M.
AU - Khan, Md Jobair
AU - Kim, Yun Jin
AU - Kolahi, Ali Asghar
AU - Korzh, Oleksii
AU - Koteeswaran, Rajasekaran
AU - Krishnamoorthy, Vijay
AU - Kumar, G. Anil
AU - Kumar, Narinder
AU - Lee, Sang woong
AU - Lim, Stephen S.
AU - Lobo, Stany W.
AU - Lucchetti, Giancarlo
AU - Malekpour, Mohammad Reza
AU - Malik, Ahmad Azam
AU - Mandarano-Filho, Luiz Garcia Garcia
AU - Martini, Santi
AU - Mentis, Alexios Fotios A.
AU - Mesregah, Mohamed Kamal
AU - Mestrovic, Tomislav
AU - Mirrakhimov, Erkin M.
AU - Misganaw, Awoke
AU - Mohammadpourhodki, Reza
AU - Mokdad, Ali H.
AU - Momtazmanesh, Sara
AU - Morrison, Shane Douglas
AU - Murray, Christopher J. L.
AU - Nassereldine, Hasan
AU - Netsere, Henok Biresaw
AU - Neupane Kandel, Sandhya
AU - Owolabi, Mayowa O.
AU - Panda-Jonas, Songhomitra
AU - Pandey, Anamika
AU - Pawar, Shrikant
AU - Pedersini, Paolo
AU - Pereira, Jeevan
AU - Radfar, Amir
AU - Rashidi, Mohammad Mahdi
AU - Rawaf, David Laith
AU - Rawaf, Salman
AU - Rawassizadeh, Reza
AU - Rayegani, Seyed Mansoor
AU - Ribeiro, Daniela
AU - Roever, Leonardo
AU - Saddik, Basema
AU - Sahebkar, Amirhossein
AU - Salehi, Sana
AU - Sanchez Riera, Lidia
AU - Sanmarchi, Francesco
AU - Santric-Milicevic, Milena M.
AU - Shahabi, Saeed
AU - Shaikh, Masood Ali
AU - Shaker, Elaheh
AU - Shannawaz, Mohammed
AU - Sharma, Rajendra
AU - Sharma, Saurab
AU - Shetty, Jeevan K.
AU - Shiri, Rahman
AU - Shobeiri, Parnian
AU - Silva, Diego Augusto Santos
AU - Singh, Ambrish
AU - Singh, Jasvinder A.
AU - Singh, Surjit
AU - Skou, Søren T.
AU - Slater, Helen
AU - Soltani-Zangbar, Mohammad Sadegh
AU - Starodubova, Antonina V.
AU - Tehrani-Banihashemi, Arash
AU - Valadan Tahbaz, Sahel
AU - Valdez, Pascual R.
AU - Vo, Bay
AU - Vu, Linh Gia
AU - Wang, Yuan Pang
AU - Yahyazadeh Jabbari, Seyed Hossein
AU - Yonemoto, Naohiro
AU - Yunusa, Ismaeel
AU - March, Lyn M.
AU - Ong, Kanyin Liane
AU - Vos, Theo
AU - Kopec, Jacek A.
N1 - Copyright the Author(s) 2023. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.
PY - 2023/9
Y1 - 2023/9
N2 - Background: Osteoarthritis is the most common form of arthritis in adults, characterised by chronic pain and loss of mobility. Osteoarthritis most frequently occurs after age 40 years and prevalence increases steeply with age. WHO has designated 2021–30 the decade of healthy ageing, which highlights the need to address diseases such as osteoarthritis, which strongly affect functional ability and quality of life. Osteoarthritis can coexist with, and negatively effect, other chronic conditions. Here we estimate the burden of hand, hip, knee, and other sites of osteoarthritis across geographies, age, sex, and time, with forecasts of prevalence to 2050. Methods: In this systematic analysis for the Global Burden of Disease Study, osteoarthritis prevalence in 204 countries and territories from 1990 to 2020 was estimated using data from population-based surveys from 26 countries for knee osteoarthritis, 23 countries for hip osteoarthritis, 42 countries for hand osteoarthritis, and US insurance claims for all of the osteoarthritis sites, including the other types of osteoarthritis category. The reference case definition was symptomatic, radiographically confirmed osteoarthritis. Studies using alternative definitions from the reference case definition (for example self-reported osteoarthritis) were adjusted to reference using regression models. Osteoarthritis severity distribution was obtained from a pooled meta-analysis of sources using the Western Ontario and McMaster Universities Arthritis Index. Final prevalence estimates were multiplied by disability weights to calculate years lived with disability (YLDs). Prevalence was forecast to 2050 using a mixed-effects model. Findings: Globally, 595 million (95% uncertainty interval 535–656) people had osteoarthritis in 2020, equal to 7·6% (95% UI 6·8–8·4) of the global population, and an increase of 132·2% (130·3–134·1) in total cases since 1990. Compared with 2020, cases of osteoarthritis are projected to increase 74·9% (59·4–89·9) for knee, 48·6% (35·9–67·1) for hand, 78·6% (57·7–105·3) for hip, and 95·1% (68·1–135·0) for other types of osteoarthritis by 2050. The global age-standardised rate of YLDs for total osteoarthritis was 255·0 YLDs (119·7–557·2) per 100 000 in 2020, a 9·5% (8·6–10·1) increase from 1990 (233·0 YLDs per 100 000, 109·3–510·8). For adults aged 70 years and older, osteoarthritis was the seventh ranked cause of YLDs. Age-standardised prevalence in 2020 was more than 5·5% in all world regions, ranging from 5677·4 (5029·8–6318·1) per 100 000 in southeast Asia to 8632·7 (7852·0–9469·1) per 100 000 in high-income Asia Pacific. Knee was the most common site for osteoarthritis. High BMI contributed to 20·4% (95% UI –1·7 to 36·6) of osteoarthritis. Potentially modifiable risk factors for osteoarthritis such as recreational injury prevention and occupational hazards have not yet been explored in GBD modelling. Interpretation: Age-standardised YLDs attributable to osteoarthritis are continuing to rise and will lead to substantial increases in case numbers because of population growth and ageing, and because there is no effective cure for osteoarthritis. The demand on health systems for care of patients with osteoarthritis, including joint replacements, which are highly effective for late stage osteoarthritis in hips and knees, will rise in all regions, but might be out of reach and lead to further health inequity for individuals and countries unable to afford them. Much more can and should be done to prevent people getting to that late stage. Funding: Bill & Melinda Gates Foundation, Institute of Bone and Joint Research, and Global Alliance for Musculoskeletal Health.
AB - Background: Osteoarthritis is the most common form of arthritis in adults, characterised by chronic pain and loss of mobility. Osteoarthritis most frequently occurs after age 40 years and prevalence increases steeply with age. WHO has designated 2021–30 the decade of healthy ageing, which highlights the need to address diseases such as osteoarthritis, which strongly affect functional ability and quality of life. Osteoarthritis can coexist with, and negatively effect, other chronic conditions. Here we estimate the burden of hand, hip, knee, and other sites of osteoarthritis across geographies, age, sex, and time, with forecasts of prevalence to 2050. Methods: In this systematic analysis for the Global Burden of Disease Study, osteoarthritis prevalence in 204 countries and territories from 1990 to 2020 was estimated using data from population-based surveys from 26 countries for knee osteoarthritis, 23 countries for hip osteoarthritis, 42 countries for hand osteoarthritis, and US insurance claims for all of the osteoarthritis sites, including the other types of osteoarthritis category. The reference case definition was symptomatic, radiographically confirmed osteoarthritis. Studies using alternative definitions from the reference case definition (for example self-reported osteoarthritis) were adjusted to reference using regression models. Osteoarthritis severity distribution was obtained from a pooled meta-analysis of sources using the Western Ontario and McMaster Universities Arthritis Index. Final prevalence estimates were multiplied by disability weights to calculate years lived with disability (YLDs). Prevalence was forecast to 2050 using a mixed-effects model. Findings: Globally, 595 million (95% uncertainty interval 535–656) people had osteoarthritis in 2020, equal to 7·6% (95% UI 6·8–8·4) of the global population, and an increase of 132·2% (130·3–134·1) in total cases since 1990. Compared with 2020, cases of osteoarthritis are projected to increase 74·9% (59·4–89·9) for knee, 48·6% (35·9–67·1) for hand, 78·6% (57·7–105·3) for hip, and 95·1% (68·1–135·0) for other types of osteoarthritis by 2050. The global age-standardised rate of YLDs for total osteoarthritis was 255·0 YLDs (119·7–557·2) per 100 000 in 2020, a 9·5% (8·6–10·1) increase from 1990 (233·0 YLDs per 100 000, 109·3–510·8). For adults aged 70 years and older, osteoarthritis was the seventh ranked cause of YLDs. Age-standardised prevalence in 2020 was more than 5·5% in all world regions, ranging from 5677·4 (5029·8–6318·1) per 100 000 in southeast Asia to 8632·7 (7852·0–9469·1) per 100 000 in high-income Asia Pacific. Knee was the most common site for osteoarthritis. High BMI contributed to 20·4% (95% UI –1·7 to 36·6) of osteoarthritis. Potentially modifiable risk factors for osteoarthritis such as recreational injury prevention and occupational hazards have not yet been explored in GBD modelling. Interpretation: Age-standardised YLDs attributable to osteoarthritis are continuing to rise and will lead to substantial increases in case numbers because of population growth and ageing, and because there is no effective cure for osteoarthritis. The demand on health systems for care of patients with osteoarthritis, including joint replacements, which are highly effective for late stage osteoarthritis in hips and knees, will rise in all regions, but might be out of reach and lead to further health inequity for individuals and countries unable to afford them. Much more can and should be done to prevent people getting to that late stage. Funding: Bill & Melinda Gates Foundation, Institute of Bone and Joint Research, and Global Alliance for Musculoskeletal Health.
UR - http://www.scopus.com/inward/record.url?scp=85168323463&partnerID=8YFLogxK
U2 - 10.1016/S2665-9913(23)00163-7
DO - 10.1016/S2665-9913(23)00163-7
M3 - Article
C2 - 37675071
AN - SCOPUS:85168323463
SN - 2665-9913
VL - 5
SP - e508-e522
JO - The Lancet Rheumatology
JF - The Lancet Rheumatology
IS - 9
ER -